657 related articles for article (PubMed ID: 26267817)
1. Immunogenicity and sustainability of the immune response in Brazilian HIV-1-infected individuals vaccinated with inactivated triple influenza vaccine.
Souza TM; Santini-Oliveira M; Martorelli A; Luz PM; Vasconcellos MT; Giacoia-Gripp CB; Morgado M; Nunes EP; Lemos AS; Ferreira AC; Moreira RI; Veloso VG; Siqueira M; Grinsztejn B; Camacho LA
J Med Virol; 2016 Mar; 88(3):426-36. PubMed ID: 26267817
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186
[TBL] [Abstract][Full Text] [Related]
3. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety.
Madhi SA; Maskew M; Koen A; Kuwanda L; Besselaar TG; Naidoo D; Cohen C; Valette M; Cutland CL; Sanne I
Clin Infect Dis; 2011 Jan; 52(1):128-37. PubMed ID: 21148531
[TBL] [Abstract][Full Text] [Related]
4. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
[TBL] [Abstract][Full Text] [Related]
6. Short communication: immunogenicity of an inactivated influenza vaccine and postvaccination influenza surveillance in HIV-infected and noninfected children and adolescents.
Machado AA; Machado CM; Boas LS; Lopes MC; Gouvêa Ade F; Succi RC; Mendoza TR; Kanashiro TM; Machado DM
AIDS Res Hum Retroviruses; 2011 Sep; 27(9):999-1003. PubMed ID: 21284525
[TBL] [Abstract][Full Text] [Related]
7. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.
Kang EK; Eun BW; Kim NH; Lim JS; Lee JA; Kim DH
BMC Infect Dis; 2016 Aug; 16(1):438. PubMed ID: 27549626
[TBL] [Abstract][Full Text] [Related]
8. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
Roggelin L; Vinnemeier CD; Meyer S; Witte K; Marx L; Theeß W; Burchard GD; Rolling T; Cramer JP
Hum Vaccin Immunother; 2015; 11(10):2370-5. PubMed ID: 26114800
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
[TBL] [Abstract][Full Text] [Related]
11. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
Front Immunol; 2018; 9():2465. PubMed ID: 30405641
[No Abstract] [Full Text] [Related]
12. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
[TBL] [Abstract][Full Text] [Related]
13. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine.
Seo YB; Lee J; Song JY; Choi HJ; Cheong HJ; Kim WJ
Hum Vaccin Immunother; 2016; 12(2):478-84. PubMed ID: 26431466
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
Vinnemeier CD; Fischer-Herr J; Meyer S; Liebig K; Theeß W; Burchard GD; Cramer JP
Hum Vaccin Immunother; 2014; 10(2):441-8. PubMed ID: 24240428
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
[TBL] [Abstract][Full Text] [Related]
17. Cross-protection against homologous drift variants of influenza A and B after vaccination with split vaccine.
Heckler R; Baillot A; Engelmann H; Neumeier E; Windorfer A
Intervirology; 2007; 50(1):58-62. PubMed ID: 17164559
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
[TBL] [Abstract][Full Text] [Related]
19. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
[TBL] [Abstract][Full Text] [Related]
20. The effect of age and recent influenza vaccination history on the immunogenicity and efficacy of 2009-10 seasonal trivalent inactivated influenza vaccination in children.
Ng S; Ip DK; Fang VJ; Chan KH; Chiu SS; Leung GM; Peiris JS; Cowling BJ
PLoS One; 2013; 8(3):e59077. PubMed ID: 23554974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
